Vés al contingut

An adaptive, Phase 2, double-blind, randomized, placebo-controlled, multicenter study to evaluate the safety, tolerability, immunogenicity, and pharmacodynamic effects of ACI-7104.056 in patients with early stages of Parkinson’s disease

Obert
  • Codi protocol: ACI-7104-PD-2103
  • Codi EudraCT: No aplica
  • Grup de recerca: Malalties Neurodegeneratives
  • Servei: Neurologia
  • Investigador/a principal:  Hernández Vara, Jorge
  • Malaltia: Malalties del sistema nerviós
  • Fase: Fase II
  • Estat: Reclutant voluntaris